REGENERX BIOPHARMACEUTICALS
RGN
RGN was delisted on the 22nd of December, 2010.
2 hedge funds and large institutions have $103K invested in REGENERX BIOPHARMACEUTICALS in 2020 Q4 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
16% more capital invested
Capital invested by funds: $89K → $103K (+$14K)
0% more funds holding
Funds holding: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WJWM
Williams Jones Wealth Management
New York
|
+$4.43K |
Top Sellers
RGN Hedge Fund Activity: Q4 2020 in Review
2 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in REGENERX BIOPHARMACEUTICALS (RGN) for Q4 2020, worth a combined $103K — up 16% from $89K a quarter earlier.
Fund positioning in RGN was balanced in Q4 2020: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Williams Jones Wealth Management, adding an estimated $4.43K.
- 2 institutional investors held REGENERX BIOPHARMACEUTICALS (RGN) as of Q4 2020, unchanged from Q3 2020.
- Funds reported $103K of REGENERX BIOPHARMACEUTICALS stock for Q4 2020, up 16% quarter-over-quarter.
- 0 funds opened new REGENERX BIOPHARMACEUTICALS positions in Q4 2020 and 0 closed out.
- The largest REGENERX BIOPHARMACEUTICALS buyer in Q4 2020 was Williams Jones Wealth Management, an estimated $4.43K added.
Based on aggregated 13F filings for Q4 2020.